Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

| Introduce 04/03/13 | d 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01 | /09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, |
|-----------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------|
| Name o | of entity | |
| BlackEa | rth Minerals NL | |
| | | |
| ABN | | |
| 66 610 | 168 191 | |
| | | |
| We (the | e entity) give ASX the following information | • |
| Part 1 - | All issues | |
| You mu | st complete the relevant sections (attach sh | eets if there is not enough space). |
| 1 | *Class of *securities issued or to be | Fully paid ordinary shares (BEM) |
| | issued | Unlisted Options |
| | | 20 245 250 2514 |
| 2 | Number of *securities issued or to be issued (if known) or maximum | 28,016,068 BEM |
| | number which may be issued | 4,000,000 options (unlisted) |
| | · | |
| 2 | 5 | Exercise Price - \$0.08 |
| 3 | Principal terms of the *securities (e.g. if options, exercise price and | Expiring - 29 August 2022 |
| | expiry date; if partly paid | |
| | †securities, the amount | |
| | outstanding and due dates for | |
| | payment; if +convertible securities, | |
| | the conversion price and dates for | |
| | conversion) | 1 |

⁺ See chapter 19 for defined terms.

Unlisted options - No - only on exercise into BEM all respects from the +issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend. interest distribution or payment 5 Issue price or consideration BEM - 6 cents Unlisted options - Nil The funds raised for graphite projects in Southern 6 Purpose of the issue Madagascar and in particular: (If issued as consideration for the • Bulk trial mining and export of ore to a pilot plant; acquisition of assets, clearly Pilot trial; identify those assets) BFS (feasibility) related activities / consultants / contractors; and Working Capital Unlisted options issue - for services provided by Peloton Capital or nominess Yes 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 30 November 2018 6b resolution under rule 7.1A was passed BEM - 3,016,068 6c Number of *securities issued Unlisted options - 4,000,000 without security holder approval under rule 7.1 6d Number of *securities issued with security holder approval under rule 7.1A

BEM issue - Yes

4

Do the *securities rank equally in

⁺ See chapter 19 for defined terms.

| 6e | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | BEM – 25,000,000 |) (General N | Meeting 30 May 2019) |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|--------------|----------------------------------|
| | | | | |
| 6f | Number of *securities issued under an exception in rule 7.2 | - | | |
| 6g | If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation. | - | | |
| | | | | |
| 6h | If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | - | | |
| | | | | |
| 6i | Calculate the entity's remaining | rule 7.1 | 9, | 579,850 |
| | issue capacity under rule 7.1 and | rule 7.1A | 11, | 063,945 |
| | rule 7.1A – complete Annexure 1 and release to ASX Market Announcements | Total | | 643,795 |
| | , uniounicine | | | |
| 7 | ⁺ Issue dates | 29 August 2019 | | |
| | Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. | | | |
| | Cross reference: item 33 of Appendix 3B. | | | |
| | | | | |
| | | Number | | ⁺ Class |
| 8 | Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable) | 86,945,521 | | BEM - Fully paid ordinary shares |

⁺ See chapter 19 for defined terms.

| | | Number | ⁺ Class |
|-------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| 9 | Number and *class of all *securities not quoted on ASX (<i>including</i> the *securities in section 2 if | 26,710,000 | Fully paid ordinary shares restricted for 24 months until 19/01/2020 |
| applicable) | 20,432,750 | Partly paid contributing shares paid to \$0.0001 each (\$0.2499 unpaid) | |
| | | 7,710,000 | Partly paid contributing shares paid to \$0.0001 each (\$0.2499 unpaid) restricted for 24 months until 19/01/2020 |
| | | 2,750,000 | Options with an exercise price of \$0.30 with an expiry date of 22 June 2020 restricted for 24 months until 19/01/2020 |
| | | 8,000,000 | Performance Rights as approved by shareholders on 30 November 2018 |
| | | 4,000,000 | Options with an exercise price of \$0.08 with an expiry date of 29 Aug 2022 |
| 10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | - | |
| Part 2 - P | ro rata issue | | |
| 11 | Is security holder approval required? | N/A | |
| 12 | Is the issue renounceable or non-renounceable? | | |
| 13 | Ratio in which the *securities will be offered | | |
| 14 | [†] Class of [†] securities to which the offer relates | | |
| 15 | [†] Record date to determine entitlements | | |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | | |

⁺ See chapter 19 for defined terms.

| 17 | Policy for deciding entitlements in relation to fractions | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| | | |
| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents | |
| | Note: Security holders must be told how their entitlements are to be dealt with. | |
| | Cross reference: rule 7.7. | |
| 19 | Closing date for receipt of acceptances or renunciations | |
| 20 | | |
| 20 | Names of any underwriters | |
| | | |
| 21 | Amount of any underwriting fee or commission | |
| | | Г |
| 22 | Names of any brokers to the issue | |
| | | L |
| 23 | Fee or commission payable to the broker to the issue | |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders | |
| | | |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting | |
| | | Г |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled | |
| | | |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | |
| 20 | Data vights trading will begin the | |
| 28 | Date rights trading will begin (if applicable) | |
| 20 | Data rights trading will and life | |
| 29 | Date rights trading will end (if applicable) | |

⁺ See chapter 19 for defined terms.

| 30 | How do security holders sell their entitlements in full through a broker? |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? |
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)? |
| 33 | †Issue date |
| | Quotation of securities only complete this section if you are applying for quotation of securities |
| 34 | Type of *securities (tick one) |
| (a) | *Securities described in Part 1 |
| (b) | All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities |
| Entitie | s that have ticked box 34(a) |
| Addition | al securities forming a new class of securities |
| Tick to docume | indicate you are providing the information or ints |
| 35 | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders |
| 36 | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over |
| 37 | A copy of any trust deed for the additional *securities |

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

| 38 | Number of *securities for which *quotation is sought | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|
| 39 | ⁺ Class of ⁺ securities for which quotation is sought | | |
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | | |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security) | | |
| 42 | Number and *class of all *securities quoted on ASX (<i>including</i> the *securities in clause 38) | Number | †Class |

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.

give this warranty

- The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those *securities should not be granted *quotation.
- An offer of the *securities for sale within 12 months after their issue will not require
 disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
 Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to
- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Company Secretary Date: 29 August 2019

Print name: Simon Storm

== == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

| Rule 7.1 – Issues exceeding 15% of capital | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-------------------------------------------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | | |
| Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue | 60,785,500 | | |
| Add the following: Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2 | -, -, | chase Plan 28-Mar-19 f perf rights 05-Jul-19 | |
| Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval | 678,334 Approved | 30 May 19 30 May 19 30 May 19 | |
| Number of partly paid †ordinary securities that became fully paid in that 12 month period | | | |
| Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | | |
| Subtract the number of fully paid *ordinary securities cancelled during that 12 month period | | | |
| "A" | 110,639,453 | | |

⁺ See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A" | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|--|--|
| "B" | 0.15 | | |
| | [Note: this value cannot be changed] | | |
| Multiply "A" by 0.15 | 16,595,918 | | |
| Step 3: Calculate "C", the amount of plants already been used | acement capacity under rule 7.1 that | | |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued: | 4,000,000 – options issue 29 Aug 19 3,016,068 – share placement 29 Aug 19 | | |
| Under an exception in rule 7.2 | | | |
| Under rule 7.1A | | | |
| With security holder approval under rule 7.1 or rule 7.4 | | | |
| Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | | | |
| "C" | 7,016,068 | | |
| Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1 | | | |
| "A" x 0.15 | 16,595,918 | | |
| Note: number must be same as shown in Step 2 | | | |
| Subtract "C" | 7,016,068 | | |
| Note: number must be same as shown in Step 3 | | | |
| <i>Total</i> ["A" x 0.15] – "C" | 9,579,850 | | |
| | [Note: this is the remaining placement capacity under rule 7.1] | | |

⁺ See chapter 19 for defined terms.

| Rule 7.1A – Additional placem | ent capacity for eligible entities | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--|
| Step 1: Calculate "A", the base figure from which the placement capacity is calculated | | |
| "A" | 110,639,453 | |
| Note: number must be same as shown in Step 1 of Part 1 | | |
| Step 2: Calculate 10% of "A" | | |
| "D" | 0.10 Note: this value cannot be changed | |
| Multiply "A" by 0.10 | 11,063,945 | |
| Step 3: Calculate "E", the amount of pl has already been used | acement capacity under rule 7.1A that | |
| Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A | - | |
| Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | | |
| "E" | - | |
| Step 4: Subtract "E" from ["A" x "D"] to capacity under rule 7.1A | o calculate remaining placement | |
| "A" x 0.10 | 11,063,945 | |
| Note: number must be same as shown in Step 2 | | |
| Subtract "E" | - | |
| Note: number must be same as shown in Step 3 | | |
| <i>Total</i> ["A" x 0.10] – "E" | 11,063,945 Note: this is the remaining placement capacity under rule 7.1A | |

⁺ See chapter 19 for defined terms.